STAT Summit: The hypebusters who spoke truth to power
Dr. Otis Brawley, a professor of oncology and epidemiology, and Joel Dudley, senior vice president of research at Tempus, spoke about hype in science.
Dr. Otis Brawley, a professor of oncology and epidemiology, and Joel Dudley, senior vice president of research at Tempus, spoke about hype in science.
Regeneron plans to buy 23andMe out of bankruptcy for $256 million, potentially bringing to a close the saga of the consumer genetics firm
The FDA finally approved Novavax’s Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do not face
Health insurers continue to use algorithms to predict how long patients need intense care — and thus how much care is covered, an attorney says.…
The grant termination letters say there are no appeals. Yet dozens of appeals have succeeded as biomedical researchers lobby and sue to restore funding.
No longer will our medicines be gated through animals, but rather through entirely human systems — leading to breakthrough options for the humans that need…
The NIH is “reducing animal use in research.” But there is no replacement for animal models.
Høeg has been skeptical of the safety and value of some vaccines and mandates, raising questions about her approach at the FDA.
Research into breast cancer, infectious diseases, longevity, and ALS is at risk.
Open Doors ‘22 is a new civic collaboration that brings together the most creative minds working in health, medicine, and the life sciences.
Calling everyone working in health and life sciences! Join STAT in NYC on June 5 for free drinks, light bites, and networking at Elevate Labs.